Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins

Alison Smith, Hugh Manoli, Stacey Jaw, Kimberley Frutoz, Alan L. Epstein, Leslie A. Khawli, and Frank-Peter Theil

1Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA 90089, USA
2Nonclinical Development, UCB Biopharma SPRL, 1420 Braine-l’Alleud, Belgium

Correspondence should be addressed to Leslie A. Khawli; lkhawli@usc.edu and Frank-Peter Theil; peter.theil@ucb.com

Received 7 March 2016; Accepted 12 July 2016

Academic Editor: Douglas C. Hooper

Copyright © 2016 Alison Smith et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Biologics have emerged as a powerful and diverse class of molecular and cell-based therapies that are capable of replacing enzymes, editing genomes, targeting tumors, and more. As this complex array of tools arises a distinct set of challenges is rarely encountered in the development of small molecule therapies. Biotherapeutics tend to be big, bulky, polar molecules comprised of protein and/or nucleic acids. Compared to their small molecule counterparts, they are fragile, labile, and heterogeneous. Their biodistribution is often limited by hydrophobic barriers which often restrict their administration to either intravenous or subcutaneous entry routes. Additionally, their potential for immunogenicity has proven to be a challenge to developing safe and reliably efficacious drugs. Our discussion will emphasize immunogenicity in the context of therapeutic proteins, a well-known class of biologics. We set out to describe what is known and unknown about the mechanisms underlying the interplay between antigenicity and immune response and their effect on the safety, efficacy, pharmacokinetics, and pharmacodynamics of these therapeutic agents.

1. Introduction

Biologics are some of the most promising innovations in modern drug therapy and represent a diverse array of molecular tools ranging in complexity and size. These biologically derived therapeutic agents are engineered by exploiting molecular and cellular machinery already found in nature. They are capable of performing complex and precise functions; their medicinal applications are seemingly endless. They greatly differ from the more traditional concept of a drug: the small molecule. Small molecules are typically orally administered, lipophilic, organic compounds that are low in molecular weight (<900 Da) and a nanometer in size [1]. These characteristics allow them to diffuse throughout the body, binding promiscuously to both target and off-target sites. On the other hand, biologics encompass a wide range of biomolecular products ranging in size from short peptides to organs for transplantation [2–5]. As these products increase in size and complexity, so do their molecular and functional profiles.

Biotherapeutics are a subclass of biologics that are synthesized using recombinant DNA and/or hybridoma technologies. They include monoclonal antibodies, cytokines, growth factors, hormones, and other regulatory peptides [6]. They differ from small molecule drugs in that they are often hydrophilic and interact with a far more discrete set of targets making them an attractive alternative to traditional small molecule therapies associated with severe toxicities such as chemotherapeutics and immunosuppressants. For instance, antitumor antibodies can be conjugated to small molecule payloads, markedly decreasing the effective dose and toxic effects of the moiety. Once considered science fiction, the advancement of biologic technology has made treatments like enzyme replacement therapies, gene therapy, and tissue engineering a reality.

Biologics have some clear advantages over small molecule drugs, but they are not a panacea. Due to their high antigenic potential, biologics frequently stimulate an immunogenic response [7, 8]. Some clinical investigations of a biotherapeutic have reported antidrug antibody (ADA) formation...
incidence rates in >90% of patients [9–12]. These immunogenic responses sometimes result in altered efficacy and immunotoxicity profiles that can vary from patient to patient. Immunogenicity-related adverse events (AEs) may be as benign as a mild itchy rash or as serious as infusion reactions, anaphylaxis, and cytokine release syndrome (CRS) [13,14]. As an example, tumor necrosis factor (TNF) inhibitors can activate autoantibodies leading to Drug-Induced Autoimmunity (DIA) [15]. Luckily, the majority of immunogenic responses are not toxic and do not lead to sustained autoimmune pathologies. Rather, encounters with ADAs affect efficacy by either accelerating or impeding clearance [16, 17]. It is in these instances that immunogenicity complicates the interplay of pharmacokinetics (PK) and pharmacodynamics (PD), which further obfuscates the development of a reliable preclinical model correlating with clinical events. Without these data, research and development (R&D) are severely impaired, further potentiating the already abysmal attrition rates (85.2%) of biologics once they reach phase 1 clinical trials [18]. As the library of biologics continues to grow, so does our need to understand how immunogenicity affects efficacy and safety. Here we set out to describe the biology of immunogenic response and its impact on the PK/PD of biologics. We do this in an effort to shed light on the challenges and pitfalls facing the successful development of safe and efficacious biologics.

2. Immunogenic Risk Factors and the Need for Predictive Tools

Attributes of both the biologic and the patient contribute to the risk of immunogenic response. The antigenicity of a therapy along with patient immune status can be used to predict the occurrence and severity of a potential immunogenic response. Patients with hyperreactive immune disease, autoimmunity, or history of biotherapeutic administration are all at an increased risk of reactions against biologics. Conversely, immunosuppressed patients are less likely to mount a response [19, 20]. Hypervigilant immune systems can be especially problematic when treating autoimmune diseases with biotherapeutics. For instance, an observational study monitored patients being treated for Crohn’s disease with infliximab (IFX), a chimeric anti-TNF-alpha therapy [21]. It was found that patients with high anti-IFX-alpha antibodies in serum and low trough IFX levels correlated with lowered efficacy or poor IFX persistence. These clinical observations and immunoassays generated a PK profile of IFX that allowed clinicians to monitor Crohn’s patients for bioanalytical markers that predicted treatment outcomes in the context of ADA. Nonetheless, this kind of data is often not applicable to biosimilars or other biotherapeutics and is difficult to validate across institutions administering identical therapies due to variances in sample collection, in vitro immunoassays, data analysis, and records. In order to standardize the clinical assessment of immunogenic response, procedures and standards must be applied and interpreted by predetermined criteria. The US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) provide regulatory documents detailing such guidelines [22–24].

Genetically derived markers predicting immunogenicity could potentially be applied across all treatment groups and even across biotherapies. For instance, the Human Leukocyte Antigen (HLA) genes that encode for Major Histocompatibility Complex (MHC) class II haplotypes have been shown to play a role in the immunogenic response [25, 26]. A clinical study monitored patients diagnosed with Multiple Sclerosis (MS) treated with Interferon-Beta (INF-β). An association between a common MHC class II allele (DRBI*0701), present in 23% of the patients studied, and an increased likelihood of producing an ADA response against INF-β was discovered. Screening for this allele could guide future treatment plan decisions of MS patients. Establishing reliable and clinically relevant PK profiles of biotherapeutics and identifying genetic markers predictive of immunogenicity will allow clinicians to more effectively monitor and guide biotherapeutic administration.

2.1. Predicting Antigenicity. From discovery to clinic, immunogenicity must constantly be monitored, yet our current preclinical models have poor predictive power for clinically relevant immunogenicity [27]. For example, humanized therapies are designed to evade the immune system of patients, yet they are inherently antigenic in immunocompetent animal models and often exaggerate the antigenicity of the therapeutic agent. Nevertheless, the effort to combine preclinical data from in silico, in vitro, and in vivo methods remains worthwhile and may one day yield valid criteria for immunogenicity risk assessment.

In silico computational tools have broad applications in the identification and assessment of antigenicity. Some screen for leads such as cancer neoantigens and peptides for vaccine targets [28–30]. Others troubleshoot antigenicity by optimizing the design of peptide nanoparticles or by determining deimmunization methods for antileukemic L-asparaginase [31, 32]. As this technology matures and provides more reliable predictions, we will improve our ability to navigate the effects of immunogenicity.

In vitro modelling of antigenicity utilizes T cell assays, B cell assays, and mimotopes to identify potentially immunogenic epitopes [33, 34], whereas in vitro characterization of immunogenic response from serum samples includes qualitative and quasiquantitative immunoassays such as enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and immunoradiometric assays (IRMAs) [35]. Cell-based assays remain a popular choice for modeling antigenicity via the immunophenotyping, proliferation tracking, and cytokine secretion profiling of immune cells [36, 37]. However, these techniques remain costly since they are labor and time intensive. In vitro modeling and in vitro characterization work together to describe mechanisms of immune activation as well as immunogenic markers/phenotypes belonging to both disease and nondisease states. Ideally, this information can be used to predict the magnitude and frequency of immunogenic response and to discern which patients are most at risk of developing this response. The limitations of the clinical utility of in vitro assays for immunogenic marker discovery were discussed in a previous section. However, predictive preclinical in vitro assays would help protect both
patients and companies from the expense and risk associated with failed clinical trials. The development of such assays can be informed by selecting clinically tested therapeutic proteins and then validated if the clinically observed antibody response can be reconstructed in the preclinical setting [38]. Expanding the repertoire of valid yet simplified assays will push forward our preclinical evaluation of biologic design hopefully improving biologic design at its earliest stages.

Preclinical in vivo methods monitoring the antigenicity of a therapy have failed to correlate with clinical events and are considered to have low predictive value for immunogenic response in humans according to the International Conference on Harmonisation (ICH) S6 guidance. However, they still hold value in the preclinical investigation of immunogenicity [39]. Nonhuman primates have proved successful in the modeling of toxicology, but an analysis of their use in nonclinical trials revealed that they are not successful in the modeling of toxicology, but an analysis of immunogenicity [39]. Consequently, researchers are still searching for ways to model human immunogenic response in vivo. One strategy is to engineer transgenic mice to express human antigens that tolerate them to humanized biotherapeutics. In these mice, researchers were able to model immune complex aggregation and extended-dose related ADA formation which closely mirror the phenomena observed in humans [41]. Vaccines are often evaluated in transgenic mice with a humanized haplotype, which has proved to be an effective tool for predicting CD4+ T cell activation [42, 43]. Savvy strategies like these are gradually improving our preclinical in vivo investigations, howbeit animal modeling remains an unreliable predictor of clinically relevant immunogenicity.

Over the past few decades, investigators have developed sophisticated assessment strategies and significantly expanded our understanding of immunogenicity. While regulatory agencies have agreed upon and established international guidelines for certain preclinical standards, the nonclinical evaluation of allergy and pseudoallergy remains unclear [44].

3. Immunotoxicity

Immunotoxicity is not unique to biologics. Penicillin is a classic example of a potentially lethal hypersensitivity reaction to a drug therapy, and DIA can be induced via small molecule therapies as well. As early as the 1950s, drug-induced lupus was documented in response to hydralazine [45]. Since biologics have greater immunogenic potential, they are more likely to elicit immunotoxic effects. Here we will briefly discuss immunogenic response, emphasizing ADA formation, and how these can affect the toxicity profile of the therapy.

Interestingly, many biotherapeutic agents are immunomodulators capable of stimulating or suppressing immune function. This immunogenicity is engineered to accomplish a therapeutic goal, whereas unwanted immunogenic response may impair therapeutic outcome by affecting safety and/or efficacy. Immunotoxicology is associated with four derangements of immune function: immunosuppression, immunostimulation, hypersensitivity, and autoimmunity [46, 47]. These derangements can result in an unintentional blockade of endogenous function, CRS, infusion reactions, and anaphylaxis. While these AEs can have serious consequences, the majority of immunogenic response elicits mild AEs or remains clinically silent. Prior to the start of a clinical trial, it is necessary that researchers evaluate the therapy in order to establish appropriate criteria for monitoring immunogenicity and to define unacceptable immunotoxicity that would halt/end the study.

Immunologically based AEs are often ADA-mediated. The formation of ADA is triggered when the classical pathway recognizes a “foreign” antigen via antigen presentation cells or by B/T cell mediated breaking of tolerance to humanized recombinant therapies [17, 48]. The latter functions via two pathways: the T cell dependent (TD) and the T cell independent (TI) pathway. TD accounts for 90% of ADA formation and relies on antigen stimulation of CD4+ T cell, which mounts a full adaptive immune response. TD activating therapeutic agents have an epitope that engages CD4+ T cells thus generating high affinity IgGs and memory B cells leading to a more persistent and robust response. In contrast, TI-ADA are thought to arise from the direct stimulation of B cell receptors (BCRs) by molecular therapies containing patterned structural motifs, that is, polymeric repeats or carbohydrate molecules, capable of crosslinking BCRs. TI activation generates pentavalent IgM or low-affinity IgG antibodies that bypass T cell mediated affinity maturation and isotype switching. This immature antibody response fails to induce memory phenotypes. T cell epitope screening should be considered along with the construct design of the therapy in order to mitigate ADA response by either selecting for immunosuppressive phenotypes like Tregs or avoiding stable epitopes all together.

Each biologic must be evaluated case by case for potential immunotoxicity. Careful attention is required when considering bispecific antibodies, antibody drug conjugates, and other products lacking an endogenous analog since they are more likely to elicit ADA formation [49]. For instance, Hemophilia A is a life-threatening genetic disease in which patients lack an essential clotting factor and is treated with Factor VIII replacement therapy [50]. Unfortunately this therapy triggers ADA response in up to a third of patients and often worsens the condition in patients with high ADA titers. Even though supplementary recombinant proteins are often constructed from the native protein sequences already expressed in patients they can elicit ADA which also neutralized the native proteins resulting in thrombocytopenia and red-cell aplasia [51, 52]. Additionally, tissue deposition of immune complexes can precipitate disease such as nephrotic syndrome and drug-induced vasculitis [53, 54]. Preclinical models and clinical precedence can provide clues pointing to possible immunogenic outcomes of a biologic in the clinic; however, immunotoxicity remains an unpredictable threat to patient safety.

4. The Impact of Immunogenicity on PK/PD and Efficacy

In order for a therapy to be successful once it reaches market, clinicians must have confidence in its therapeutic potential
administration. Traditionally therapeutic proteins have been
GI tract; therefore they have poor bioavailability by oral
route of administration or even after the biologic is cleared,
can be affected at any stage of their journey, starting with their
reason for drug failure in phase II clinical trials is lack of
clinical efficacy [55].

Small molecules and therapeutic proteins are comprised
of entirely distinct molecular classes which are not only
distinguished by their chemical profiles but their immuno-
activity and PK profiles as well [17, 56]. Small molecule PK
profiles can be interpreted from direct measurements of the
active drug and its metabolites in serum; their ADME is well
characterized and employs simplified compartment models.
Their PD can be interpolated from relationships such as dose-
exposure-response curves and does not require a nuanced
understanding of the drug’s mechanism of action. The PK/PD
of biologics are driven by target-mediated drug disposition
(TMDD) meaning that the high affinity of the therapy for its
target (PD) strongly influences its PK. Theoretically, TMDD
should yield a large volume of distribution with a high
accumulation of therapy in its target tissue. However, tissue
uptake can be slowed by a variety of mechanisms thus
confining the therapy to its administration site. Currently, we
do not understand ADME well enough to fully describe and
characterize this interplay.

Serum measurements of biologics must consider the
unbound, partially bound, and bound forms [57–59]. Distingui-
ishing between the free and bound forms of the biologic
and its metabolites is necessary in order to identify the effec-
tive fraction of bioactive drug in circulation. The terminal
half-lives of these forms tend to vary, with the free form
often displaying the shortest half-life [60]. Many of the
well-established small molecule models employed by R&D fail
to describe the PK/PD and ADME of biotherapeutics. Addi-
tionally, unwanted and unanticipated immunogenic response
perturbs PK/PD thereby diminishing the predictive power of
preclinical data. Our inability to describe and anticipate these
phenomena hinders our ability to develop biologics that will
prove efficacious and reliable once they reach clinical trial.
Here we discuss what is known about immunogenicity’s role
in affecting PK/PD and how we hope to apply this knowledge
in order to improve the predictive power of biologic models.

4.1. The Influence and Modes of Action of Immunogenicity on
PK/PD Assessment. The immunogenic potential of biologics
can be affected at any stage of their journey, starting with their
route of administration or even after the biologic is cleared,
by leaving a lasting impression on the immunomemory
of the patient. Most biotherapeutics are large hydrophobic
molecules that cannot survive the harsh conditions of the
GI tract; therefore they have poor bioavailability by oral
administration. Traditionally therapeutic proteins have been
given intravenously (IV) maximizing bioavailability and min-
imizing immunogenic risk. However, this method is both
inconvenient and expensive. Newer formulations allow for
subcutaneous (SC), intraperitoneal, or inhalation routes [61–
63]. SC administration is more cost effective and convenient
than IV, yet it is often slow and incomplete. In particular
for large molecules (>20 kDa) that tend to migrate more
slowly through the extracellular matrix (ECM), SC poses an
increased risk of ADA formation by dendritic cells processing
which drain directly to the lymphatics. Depot formulations
can aid absorption by including ECM degrading enzymes
like hyaluronidase and by stabilizing proteins preventing
degradation and aggregation [64]. Currently we are in need of
formulations that can deliver an efficacious dose in affordable
and convenient ways.

As was previously described, myriad patient and product-
related factors can influence immunogenicity’s effect on
PK/PD and efficacy. ADAs are described by their mode of
action, classifying them as either neutralizing ADAs (nADAs)
or nonneutralizing ADAs (non-nADAs) [65]. The nADAs
interact directly with biologics and/or bind to pharmaco-
logically relevant sites, obscuring interactions between the
therapy and its target, thereby decreasing the overall efficacy.
Another classification categorizes ADA as sustaining or clear-
ing, which indicates their influence on protein drug clearance
[66]. Both nADA and non-nADA can either prolong or
shorten the half-life of biologics. Most of the time immune
complex formation, comprised of drug-ADA aggregates,
will increase the clearance of the biotherapeutic. This phe-
nomenon is most notable in patients with high affinity, high
titer ADA. In some cases, isotype interactions with Fc recep-
tors (FcR) also influence serum drug concentration. For IgGs,
binding to the neonatal FcR (FcRn) increases bioavailability,
possibly due to FcRn-mediated protection from catabolism
at the injection site and/or draining lymphatics [67, 68].
Coupling immunoprotective technologies, such as Fc fusion
proteins, with improved delivery formulations could stabilize
circulating concentrations of biotherapeutics and their over-
all bioavailability. This effect will vary from patient to patient
depending on factors like their MHC haplotypes and whether
TD-ADA versus TI-ADA are triggered. Since we do not fully
understand the patient and product-related factors governing
this response, it is difficult to establish general guidelines
defining an efficacious and reliable dosing regimen.

In order to characterize the effect of ADA on the PK
profile of a biologic, an immunogenicity profile must be
established. ADAs are a temporally evolving heterogeneous
population circulating in serum alongside a multitude of
endogenous proteins and antibodies [69, 70]. In most ani-
mal, ADAs become detectable within 2–4 weeks after the
first dose administration and around 10 days in mice. They
are usually polyclonal antibodies against multiple epitopes
comprised of more than one isotype circulating at varying
concentrations amongst a multitude of endogenous proteins.
To overcome this daunting task of identifying and classi-
\ing ADA response, a standard bioanalytical schematic is
employed: (1) sensitive screen, (2) confirmatory assay, and (3)
f\unctional characterization. The detection of these ADA is
limited to capture antibody concentrations >20–1000 ng/mL.
with Kd of K-9 to K-8, respectively [71–73]. Occasionally the therapeutic is administered at such a low dose that it is rapidly consumed by the target site. In this absence of detectable circulating drug, PD measurements of target binding can correlate drug exposure. This method of analysis can also be useful in instances where a therapeutic protein has bioactive metabolites not measured by PK assays [74].

Studies looking at therapeutic antibodies, such as natalizumab and IFX, observed an increase in clearance and a reduction in efficacy when ADAs were persistent rather than transient throughout the first 12 weeks of therapy. They also found that clearing ADA formation was detectable 8–16 weeks after treatment initiation [8, 75, 76]. These labile kinetics suggest that when a measurement is taken significantly, it impacts the interpretation of the bioanalytics; therefore, dosing and sampling schedules should be well-defined and include peak and trough measurements as well as time points sampled long after the circulating drug has been cleared. Higher concentrations of ADAs are more likely to impact PK profiles and interfere with bioanalytical measurements making simultaneous quantification of both the biologic and ADA difficult. This hampers the ability to track the time course of ADA response. As a result, the impact of immune response on biologics cannot be fully investigated and our understanding remains incomplete.

Ultimately, the development of a physiologically based pharmacokinetic (PBPK) model akin to the small molecule compartment model that also accounts for immunogenicity would be ideal. Both “top down” and “bottom up” approaches are being used to derive mathematical models of ADME. For example, biodistribution coefficients (BC) can estimate tissue specific distribution of protein fragments based on molecular weight and plasma concentrations [77]. The BC50 values for most tissues were found to be ~35 kDa. Clinical derivation of these models could be achieved with a meta-analysis of clinical PK bioanalytical data, but inconsistent reporting of bioanalytical parameters regarding ADA response makes studies incomparable between institutions [78]. Fortunately, by collecting sparse or dense samples from many clinical studies, Population PK (PopPK) allows for the inclusion of data from a variety of un-/balanced designs. Most advantageously, PopPK looks at the target population of interest receiving clinically relevant doses rather than the healthy subjects in traditional PK studies. These studies enable the identification and measurement of variances and can point to potential explanations if identifying factors (demographic, environment, and pathophysiology) are found to correlate with altered PK. Currently, groups are working to validate parameters and refine models relating PK and immunogenicity; they have yet to design a reliable model generalizable to a diverse array of biotherapeutics.

ADAs affect both the clearance and efficacy of biologics. Building off of this basic tenant we have been able to partially classify the interplay between immunogenicity and PK/PD, yet we are unable to fully describe these phenomena. Unlike the PK/PD of small molecules, which began with bioanalytical measurements that later yielded theories to describe those measurements, the PK/PD of biologics is mostly understood through its apparent differences from small molecule ADME.

We cannot rely on our current bioanalytical techniques to predict or describe PK/PD or clinical efficacy in the context immunogenic response.

5. Strategies for Overcoming the Pitfalls of Immunogenicity

As we have discussed, the PK/PD and the ADME of biologics can be dramatically affected by immunogenic response. So how then can we mitigate the consequences of those effects? We can approach this challenge from both R&D and clinical perspectives.

5.1. Biotherapeutic Production and Design. Design and manufacturing processes can mitigate or exacerbate the inherent antigenicity of biotherapeutics. Good manufacturing processes and quality assurance recognize the inherent heterogeneity of biologic batches. Antigenic impurities such as endotoxin contamination and detergents, aggregate formation, and variation in biologic activity must be kept to a minimum in order to ensure a safe and reliably efficacious product [79]. Careful handling of the protein product throughout the entire manufacturing process is critical in preventing aggregate formation. Not only are aggregated and misfolded proteins less efficacious, but also they precipitate immune complex formation and immunogenic response. Data suggest that proteins exposed to stress, freeze-thawing, and pH shifts with surface active agents or hydrophobic surfaces are more likely to form aggregates that can crosslink BCRs thereby inducing TI-ADA formation [80, 81]. Additionally, some biotherapeutics do not tolerate high concentration formulations well and may require more frequent dosing [82]. By improving production processes and conservatively administering these therapies, we can prevent the acquisition of these unnecessary antigenic properties.

Construct design is at the heart of biologic engineering. New and exciting therapies such as bispecific antibodies and antibody drug conjugates are expanding the utility and function of biotherapeutics, even so they may introduce antigenicity with their inadvertently novel structures. In fact, it was the drive to decrease antigenicity that evolved antibody therapies. Initial antibody therapies were murine-derived and found to be highly immunogenic. Eventually chimeric antibody technologies evolved until we achieved fully humanized antibodies. In theory, a humanized antibody, free of antigenic properties, should not be immunogenic. In reality, the immense variance of CD4+ T cell epitopes and MHC haplotypes allows for fully humanized antibodies to remain immunogenic in some patients [83, 84]. To mitigate this, deimmunization strategies can be used when designing protein therapeutics. This method utilizes in silico predictions of antigenic peptide sequences to identify potentially antigenic epitopes in a therapeutic protein. These peptides are then synthesized and their antigenicity is evaluated with in vitro binding assays to TCRs and MHC II receptors. Immunogenic epitopes are then mutated to a more tolerated sequence and subsequent constructs are iteratively screened. Tolerization is an ingenious twist on deimmunization that selects for and engineers biologics with Treg activating
epitopes that can induce tolerance of the biologic [85]. Combining both deimmunization with tolerization has proved an effective method for reducing immunogenic response. Posttranslational modifications of biologics also appear to influence immunogenicity. For instance, glycosylation can shield antigens from ADA binding and retard processing. In line with this finding, a synthetic kind of glycosylation known as PEGylation can prevent protein aggregation and mask antigenic epitopes thereby reducing immune response [86]. However, sometimes this process introduces an immunogenic linker. Additionally, some forms of xeno-glycation may have immunostimulatory effects. The risk is especially high when eukaryotic organisms like yeast are used to express proteins, since they may introduce their own microorganism specific glycosylation patterns. For instance, yeast posttranslational processing adds mannose glycan which can bind to mannose receptors on human immune cells [87]. Though this is not an exhaustive list of all the possible considerations that should be taken into account when developing biologics, these examples illustrate the usefulness of optimizing a biologic’s design to minimize immunogenicity.

5.2. The Clinical Approach. Clinicians already manage immunogenicity associated with a variety of pathologies and treatments such as rheumatoid arthritis and hematopoietic stem cell transplantation. Clinical strategies to mitigate immunogenic response include dose manipulation and immunosuppressive agents such as methotrexate and prednisone. Some patients diagnosed with Infantile Pompe disease formed ADAs when treated with the enzyme replacement therapy, recombinant human α-glucosidase (rhGAA) [88, 89]. A subgroup of patients form nADAs, but additional work showed that this subgroup can be tolerated against rhGAA by complementing the replacement therapy with combinatorial immunosuppressive therapy comprised of rituximab and methotrexate. Fortunately, this tolerance persisted even after termination of B cell recovery and immunosuppression. Dosing through is another method that has also proven to be a successful strategy in overcoming the deleterious effects of ADA on efficacy [90]. For MS patients receiving long term IFN-α therapy, nADAs have also proven to be problematic. Interestingly, recent studies have shown that high doses of IFN-sv32 result in lower nADA titers due to the saturation of these nADAs and the restoration of IFN-α binding to its receptor. High doses of IFN-α can also induce long term high dose tolerance of the immune system.

6. Summary and Conclusions

The advancement of biologics has revolutionized targeted therapy. By utilizing biologically derived tools we can administer drugs with complex and precise functions, which often mimic the body’s natural processes. However, it is this key characteristic of molecular mimicry that potentiates the antigenicity of biologics and leads to undesirable ADA-mediated outcomes such as immunotoxicity and decreased efficacy. ADAs against biologics can alter ADME thereby greatly confounding the interpretation of PK/PD assessments. Thus, it is vital that we develop bioanalytical tools that can reliably predict and model the complex interplay between immunogenicity and PK/PD. Outside of patient immune status and exposure history, we do not currently possess adequate tools or knowledge of immunogenic markers to identify which patient-product interactions carry an increased risk of immunogenic response. Though we described various preclinical in silico, in vitro, and in vivo tools used for immunogenic risk assessment, these methods are not recognized as predictive. We must rely on clinical investigations. As novel biotherapeutic proteins continue to shape the course of modern medicine, we must work to fill these knowledge gaps in order to ensure that patients receive safe and effective treatments.

Competing Interests

The authors declared no conflict of interests.

Acknowledgments

The authors would like to express their gratitude to Wolfgang F. Richter, Ph.D. degree holder, Michael Diaz, Ishani Synghal, and Michelle Khawli for their valuable and constructive suggestions and comments. Their willingness to give their time so generously has been very much appreciated.

References

[1] M. J. Macielag, "Chemical properties of antibacterials and their uniqueness," in Antibiotic Discovery and Development, T. J. Dougherty and M. J. Pucci, Eds., pp. 801–802, 2012.
[2] J. Maca, V. Dragalin, and P. Gallo, "Adaptive clinical trials: overview of phase iii designs and challenges," Therapeutic Innovation and Regulatory Science, vol. 48, no. 1, pp. 31–40, 2014.
[3] H. Kempf, B. Andree, and R. Zweigerdt, "Large-scale production of human pluripotent stem cell derived cardiomyocytes," Advanced Drug Delivery Reviews, vol. 96, pp. 18–30, 2016.
[4] N. Kubicki, C. Laird, L. Burdorf, R. N. Pierson III, and A. M. Azimzadeh, "Current status of pig lung xenotransplantation," International Journal of Surgery, vol. 23, pp. 247–254, 2015.
[5] A. M. Bailey, J. Arcidiacono, K. A. Benton, Z. Taraporewala, and S. Winitzky, "United states food and drug administration regulation of gene and cell therapies," Advances in Experimental Medicine and Biology, vol. 871, pp. 1–29, 2015.
[6] M. Wadhwa, I. Knezevic, H.-N. Kang, and R. Thorpe, "Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility," Biologicals, vol. 43, no. 3, pp. 298–306, 2015.
[7] C. A. Weber, P. J. Mehta, M. Ardito, L. Moise, B. Martin, and A. S. De Groot, "T cell epitope: friend or foe? Immunogenicity of biologics in context," Advanced Drug Delivery Reviews, vol. 61, no. 11, pp. 965–976, 2009.
[8] R. Ponce, I. Abad, L. Amaravadi et al., "Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies," Regulatory Toxicology and Pharmacology, vol. 54, no. 2, pp. 164–182, 2009.
[9] K. Kuus-Rechiel, L. S. Grauer, L. M. Karavodin, C. Knott, M. Krusemeier, and N. E. Kay, "Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal
antibodies?* Clinical and Diagnostic Laboratory Immunology, vol. 1, no. 4, pp. 365–372, 1994.

[10] E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis, "Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction," Current Pharmaceutical Biotechnology, vol. 3, no. 4, pp. 349–360, 2002.

[11] H. Schellekens and N. Casadevall, "Immunogenicity of recombinant human proteins: causes and consequences," Journal of Neurology, vol. 251, supplement 2, pp. II4–II9, 2004.

[12] H. Schellekens, "Immunogenicity of therapeutic proteins: clinical implications and future prospects," Clinical Therapeutics, vol. 24, no. 11, pp. 1720–1740, 2002.

[13] T. Corona, C. Leon, and L. Ostrosky-Zeichner, "Severe anaphylaxis with recombinant interferon beta," Neurology, vol. 52, no. 2, p. 425, 1999.

[14] R. Stebbings, L. Findlay, C. Edwards et al., "'Cytokine storm' in the Phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics," Journal of Immunology, vol. 179, no. 5, pp. 3325–3331, 2007.

[15] M. De Bandt, J. Sibilia, X. Le Loet et al., "Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey," Arthritis Research & Therapy, vol. 7, no. 3, pp. R54–R55, 2005.

[16] V. Jawa, L. P. Cousens, M. Awwad, E. Wakshull, H. Kropshofer, and A. S. De Groot, "T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation," Clinical Immunology, vol. 149, no. 3, pp. 534–555, 2013.

[17] H. Kropshofer and W. F. Richter, "Immunogenicity: its impact on ADME of therapeutic biologics," Pharmaceutical Sciences Encyclopedia, vol. 1, pp. 1–2, 2015.

[18] M. Hay, D. W. Thomas, J. L. Craighead, C. Economides, and J. Rosenthal, "Clinical development success rates for investigational drugs," Nature Biotechnology, vol. 32, no. 1, pp. 40–51, 2014.

[19] Y. Vugmeyster, J. Harrold, and X. Xu, "Absorption, Distribution, Metabolism, and Excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions," AAPS Journal, vol. 14, no. 4, pp. 714–727, 2012.

[20] P. Ragnhammar, H. J. Friesen, J. E. Frodin et al., "Induction of antirecombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients," Blood, vol. 84, no. 12, pp. 4078–4087, 1994.

[21] S. Ben-Horin, M. Yavzori, L. Katz et al., "The immunogenic part of infliximab is the F(ab)², but measuring antibodies to the intact infliximab molecule is more clinically useful," Gut, vol. 60, no. 1, pp. 41–48, 2011.

[22] US FDA Guidance, Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products; Revised Draft Guidance for Industry; Availability, FDA, Silver Spring, Md, USA, 2016.

[23] EMA, "Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins," Tech. Rep. EMA/CHMP/BMWP/14327/2006, EMA, London, UK, 2007.

[24] EMA, "Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use," Tech. Rep. EMA/CHMP/BMWP/86289/2010, EMA, London, UK, 2012.

[25] M. D. F. S. Barbosa, J. Vielmetter, S. Chu, D. D. Smith, and J. Jacinto, "Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity," Clinical Immunology, vol. 118, no. 1, pp. 42–50, 2006.

[26] V. Zota, A. Nemirovsky, R. Baron et al., "HLA-DR alleles in amyloid β-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele," Journal of Immunology, vol. 183, no. 5, pp. 3522–3530, 2009.

[27] V. Brinks, D. Weinbuch, M. Baker et al., "Preclinical models used for immunogenicity prediction of therapeutic proteins," Pharmaceutical Research, vol. 30, no. 7, pp. 1719–1728, 2013.

[28] A. Desrichard, A. Snyder, and T. A. Chan, "Cancer neoantigens and applications for immunotherapy," Clinical Cancer Research, vol. 22, no. 4, pp. 807–812, 2016.

[29] R. Zaheer, C. L. Klima, and T. A. McAllister, "Expeditious screening of candidate proteins for microbial vaccines," Journal of Microbiological Methods, vol. 116, pp. 53–59, 2015.

[30] P. Carlos, V. Roupie, S. Holbert et al., "In silico epitope analysis of unique and membrane associated proteins from Mycobacterium avium subsp. paratuberculosis for immunogenicity and vaccine evaluation," Journal of Theoretical Biology, vol. 384, pp. 1–9, 2015.

[31] T. A. P. F. Doll, R. Dey, and P. Burkhard, "Design and optimization of peptide nanoparticles," Journal of Nanobiotechnology, vol. 13, no. 1, article 73, 2015.

[32] L. N. Ramya and K. K. Pulicherla, "Studies on deinmunization of antileukaemic L-asparaginase to have reduced clinical immunogenicity—an in silico Approach," Pathology and Oncology Research, vol. 21, no. 4, pp. 909–920, 2015.

[33] E. M. Moussa, J. Kotarek, J. S. Blum, E. Marsal, and E. M. Topp, "Physical characterization and innate immunogenicity of aggregated intravenous immunoglobulin (IGIV) in an in vitro cell-based model," Pharmaceutical Research, vol. 33, no. 7, pp. 1736–1751, 2016.

[34] V. Dhir, M. Fort, A. Mahmood et al., "A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies," Journal of Immunotoxicology, vol. 9, no. 1, pp. 34–42, 2012.

[35] L. Yin, X. Chen, P. Vicini, B. Rup, and T. P. Hickling, "Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products," Cellular Immunology, vol. 295, no. 2, pp. 118–126, 2015.

[36] V. Rombach-Riegraf, A. C. Karle, B. Wolf et al., "Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro," PLoS ONE, vol. 9, no. 1, Article ID e86322, 2014.

[37] H. Kropshofer and T. Singer, "Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics," Journal of Immunotoxicology, vol. 3, no. 3, pp. 131–136, 2006.

[38] P. Gaitonde and S. V. Balu-Iyer, "In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting," Methods in Molecular Biology, vol. 716, pp. 267–280, 2011.

[39] V. Brinks, W. Jiskoot, and H. Schellekens, "Immunogenicity of therapeutic proteins: the use of animal models," Pharmacological Research, vol. 28, no. 10, pp. 2379–2385, 2011.

[40] P. J. K. van Meel, M. Kooijman, V. Brinks et al., "Immunogenicity of mAbs in non-human primates during nonclinical safety assessment," mAbs, vol. 5, no. 5, pp. 810–816, 2013.

[41] M. Haji Abdolvahab, A. Fazeli, A. Halim, A. S. Sediq, M. R. Fazeli, and H. Schellekens, "Immunogenicity of recombinant human interferon beta-1b in immune-tolerant transgenic mice corresponds with the biophysical characteristics of aggregates," Journal of Interferon & Cytokine Research, vol. 36, no. 4, pp. 247–257, 2016.
[42] P. Riese, S. Tittel, K. Schulze, and C. A. Guzmán, “Rodents as pre-clinical models for predicting vaccine performance in humans,” Expert Review of Vaccines, vol. 14, no. 9, pp. 1213–1225, 2015.

[43] Y. Zeng, T. Gao, G. Zhao et al., “Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation,” Human Vaccines & Immunotherapeutics, vol. 12, no. 3, pp. 829–836, 2015.

[44] J.-Y. Han, Y. Yi, A.-H. Liang et al., “Review on requirements of drug allergy or pseudoallergic reactions in pre-clinical evaluation,” Zhongguo Zhong Yao Za Zhi, vol. 40, no. 14, pp. 2685–2689, 2015.

[45] A. T. Borchers, C. L. Keen, and M. E. Gershwin, “Drug-induced lupus,” Annals of the New York Academy of Sciences, vol. 1108, pp. 166–182, 2007.

[46] J. Descotes and A. Gouraud, “Clinical immunotoxicity of therapeutic proteins,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 12, pp. 1537–1549, 2008.

[47] F. Dedeoglu, “Drug-induced autoimmunity,” Current Opinion in Rheumatology, vol. 21, no. 5, pp. 547–551, Sep 2009.

[48] A. S. De Groot and D. W. Scott, “Immunogenicity of protein therapeutics,” Trends in Immunology, vol. 28, no. 11, pp. 482–490, 2007.

[49] M. B. Hock, K. E. Thudium, M. Carrasco-Triguero, and N. F. Schwabe, “Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality,” The AAPS Journal, vol. 17, no. 1, pp. 35–43, 2015.

[50] M. Ing, N. Gupta, M. Teyssandier et al., “Immunogenicity of long-lasting recombinant factor VIII products,” Cellular Immunology, vol. 301, pp. 40–48, 2016.

[51] C. Pollock, D. W. Johnson, W. H. Hörl et al., “Pure red cell aplasia induced by erythropoiesis-stimulating agents,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 193–199, 2008.

[52] M. de Serres, B. Ellis, J. E. Dillberger et al., “Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man,” STEM CELLS, vol. 17, no. 4, pp. 203–209, 1999.

[53] T. E. Hunley, D. Corzo, M. Dudek et al., “Nephrotic syndrome complicating α-glucosidase replacement therapy for Pompe disease,” Pediatrics, vol. 114, no. 4, pp. e532–e535, 2004.

[54] R. G. Grau, “Drug-induced vasculitis: new insights and a changing line of suspects,” Current Rheumatology Reports, vol. 17, no. 12, article 71, 2015.

[55] P. van der Graaf, “Influencing early portfolio decision making using preclinical M&H: how early is early and is when is too late?” in Proceedings of the AAPS National Biotechnology Conference, San Francisco, Calif, USA, 2010.

[56] S. Shi, “Biologics: an update and challenge of their pharmacokinetics,” Current Drug Metabolism, vol. 15, no. 3, pp. 271–290, 2014.

[57] H. Salimi-Moosavi, J. Lee, B. Desilva, and G. Doellgast, “Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand,” Journal of Pharmaceutical and Biomedical Analysis, vol. 51, no. 5, pp. I128–I133, 2010.

[58] A. C. Bautista, D. Wullner, M. Moxness, J. S. Swanson, N. Chirmule, and V. Jawa, “Impact of matrix-associated soluble factors on the specificity of the immunogenicity assay,” Bioanalysis, vol. 2, no. 4, pp. 721–731, 2010.

[59] J. W. Lee, M. Kelley, L. E. King et al., “Bioanalytical approaches to quantify ‘total’ and ‘free’ therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development,” AAPS Journal, vol. 13, no. 1, pp. 99–110, 2011.

[60] M. P. Hall, C. Gegg, K. Walker et al., “Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunossay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor,” AAPS Journal, vol. 12, no. 4, pp. 576–585, 2010.

[61] W. F. Richter and B. Jacobsen, “Subcutaneous absorption of biotherapeutics: knowns and unknowns,” Drug Metabolism and Disposition, vol. 42, no. 11, pp. 1881–1889, 2014.

[62] S. Tamilvanan, N. L. Raja, B. Sa, and S. K. Basu, “Clinical concerns of immunogenicity produced at cellular levels by bio pharmaceuticals following their parenteral administration into human body,” Journal of Drug Targeting, vol. 18, no. 7, pp. 489–498, 2010.

[63] R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke, “The lung as a route for systemic delivery of therapeutic proteins and peptides,” Respiratory Research, vol. 2, no. 4, pp. 198–209, 2001.

[64] S. Rosengren, S. S. Dychter, M. A. Printz et al., “Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration,” The AAPS Journal, vol. 17, no. 5, pp. 1144–1156, 2015.

[65] M. Krishna and S. G. Nadler, “Immunogenicity to biotherapeutics—the role of anti-drug immune complexes,” Frontiers in Immunology, vol. 7, article 21, 2016.

[66] N. Chirmule, V. Jawa, and B. Meibohm, “Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy,” AAPS Journal, vol. 14, no. 2, pp. 296–302, 2012.

[67] S. A. Mousavi, M. Skorostol, C. Fladeby, R. Kjeken, N. Barois, and T. Berg, “Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIlb2,” Hepatology, vol. 46, no. 3, pp. 871–884, 2007.

[68] E. S. Ward, S. C. Devanaboyina, and R. J. Ober, “Targeting FcRn for the modulation of antibody dynamics,” Molecular Immunology, vol. 67, no. 2, pp. 131–141, 2015.

[69] G. Shankar, S. Arkin, L. Cocco et al., “Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations,” AAPS Journal, vol. 16, no. 4, pp. 658–673, 2014.

[70] J. Wang, J. Lozier, G. Johnson et al., “Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment,” Nature Biotechnology, vol. 26, no. 8, pp. 901–908, 2008.

[71] A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayanan et al., “Recommendations for the design and optimization of immunosassays used in the detection of host antibodies against biotechnology products,” Journal of Immunological Methods, vol. 289, no. 1-2, pp. 1-16, 2004.

[72] G. Shankar, V. Devanarayan, L. Amaravadi et al., “Recommendations for the validation of immunosassays used for detection of host antibodies against biotechnology products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 5, pp. 1267–1281, 2008.

[73] M. Liang, S. L. Klakamp, C. Funelas et al., “Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms,” Assay and Drug Development Technologies, vol. 5, no. 5, pp. 655–662, 2007.
[74] J. A. Lofgren, S. Dhandapani, J. J. Pennucci et al., "Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab," *Journal of Immunology*, vol. 178, no. 11, pp. 7467–7472, 2007.

[75] M. K. de Vries, G. J. Wolbink, S. O. Stapel et al., "Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation," *Annals of the Rheumatic Diseases*, vol. 66, no. 1, pp. 133–134, 2007.

[76] M. G. Tovey and C. Lallemand, "Immunogenicity and other problems associated with the use of biopharmaceuticals," *Therapeutic Advances in Drug Safety*, vol. 2, no. 3, pp. 113–128, 2011.

[77] Z. Li, B. Krippendorff, S. Sharma, A. C. Walz, T. Lavé, and D. K. Shah, "Influence of molecular size on tissue distribution of antibody fragments," *mAbs*, vol. 8, no. 1, pp. 113–119, 2016.

[78] L. Aarons, "Population pharmacokinetics: theory and practice," *British Journal of Clinical Pharmacology*, vol. 32, no. 6, pp. 669–670, 1991.

[79] S. K. Singh, "Impact of product-related factors on immunogenicity of biotherapeutics," *Journal of Pharmaceutical Sciences*, vol. 100, no. 2, pp. 354–387, 2011.

[80] K. D. Ratanji, J. P. Derrick, R. J. Dearman, and I. Kimber, "Immunogenicity of therapeutic proteins: influence of aggregation," *Journal of Immunotoxicology*, vol. 11, no. 2, pp. 99–109, 2014.

[81] A. S. Rosenberg, "Effects of protein aggregates: an immunologic perspective," *AAPS Journal*, vol. 8, no. 3, pp. E501–E507, 2006.

[82] M. J. Treuheit, A. A. Kosky, and D. N. Brems, "Inverse relationship of protein concentration and aggregation," *Pharmaceutical Research*, vol. 19, no. 4, pp. 511–516, 2002.

[83] D. R. Jandrlić, G. M. Lazić, N. S. Mitić, and M. D. Pavlović, "Software tools for simultaneous data visualization and T cell epitopes and disorder prediction in proteins," *Journal of Biomedical Informatics*, vol. 60, pp. 120–131, 2016.

[84] R. R. Mettu, T. Charles, and S. J. Landry, "CD4+ T-cell epitope prediction using antigen processing constraints," *Journal of Immunological Methods*, vol. 432, pp. 72–81, 2016.

[85] A. S. De Groot, F. Terry, L. Cousens, and W. Martin, "Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics," *Expert Review of Clinical Pharmacology*, vol. 6, no. 6, pp. 651–662, 2013.

[86] R. Jefferis, "Glycosylation as a strategy to improve antibody-based therapeutics," *Nature Reviews Drug Discovery*, vol. 8, no. 3, pp. 226–234, 2009.

[87] A. Von Delwig, D. M. Altmann, J. D. Isaacs et al., "The impact of glycosylation on HLA-DRI-restricted T cell recognition of type II collagen in a mouse model," *Arthritis and Rheumatism*, vol. 54, no. 2, pp. 482–491, 2006.

[88] Y. H. Messinger, N. J. Mendelsohn, W. Rhead et al., "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease," *Genetics in Medicine*, vol. 14, no. 1, pp. 135–142, 2012.

[89] K. P. Pratt, "Engineering less immunogenic and antigenic FVIII proteins," *Cellular Immunology*, vol. 301, pp. 12–17, 2016.

[90] F. Deisenhammer, "Interferon-beta: neutralizing antibodies, binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes," *Journal of Interferon & Cytokine Research*, vol. 34, no. 12, pp. 938–945, 2014.